Overview
Top Medical Research Studies
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Most Useful Reviews
Medical Researches
- All Researches
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
User Reviews
- All Reviews
- Positive Reviews
- Negative Reviews
Frequently Asked Questions
Cardiovascular disease (CVD) is a broad term that encompasses a range of heart and blood vessel disorders. This can include conditions such as coronary artery disease, which leads to heart attacks; cerebrovascular disease that results in strokes; and peripheral artery disease affecting blood flow to the limbs. The key risk factors for CVD often include high blood pressure, high cholesterol, obesity, smoking, a sedentary lifestyle, and diabetes. By identifying and managing these risk factors, individuals can significantly reduce their likelihood of developing cardiovascular problems.
Prevention and treatment strategies often involve lifestyle modifications such as adopting a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins, alongside engaging in regular physical activity. In some cases, medications might be necessary to control blood pressure or cholesterol levels. Regular check-ups with a healthcare provider are essential for monitoring heart health, especially for individuals with a family history of CVD. Understanding the signs and symptoms of cardiovascular issues—like chest pain, shortness of breath, or fatigue—can help in seeking timely medical attention, ultimately leading to better outcomes.
Omega-3 fish oil is a nutritional supplement derived from the fatty tissues of fish, particularly fatty fish like salmon, mackerel, and sardines. It is rich in omega-3 fatty acids, which are essential fats that the body cannot produce on its own. The most significant types of omega-3s found in fish oil are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which are known for their numerous health benefits. These include reducing inflammation, supporting heart health, and promoting brain function.
Incorporating omega-3 fish oil into your diet can be beneficial if you don’t consume enough fish regularly. Many health experts recommend oily fish as a part of a balanced diet due to their high omega-3 content. For those who find it difficult to include fish in their meals, fish oil supplements can offer a convenient alternative, providing the same essential fatty acids in concentrated form. However, it’s essential to choose high-quality supplements that are third-party tested for purity and potency to avoid contaminants such as heavy metals or other toxins that can impact health.
Omega-3 fish oil has long been touted for its potential cardiovascular benefits, and numerous studies support the notion that it can be helpful in managing overall heart health. Rich in EPA and DHA, the primary active components in fish oil, omega-3 fatty acids are known to reduce triglyceride levels, lower blood pressure, and may even decrease the risk of arrhythmias. Some research suggests that regular consumption of omega-3s can lead to a reduced risk of heart disease and stroke by improving vascular health and reducing inflammation in the body.
However, it's essential to approach this topic with a balanced perspective. While omega-3 supplements can be beneficial, they should not be seen as a standalone solution for cardiovascular disease. Incorporating omega-3s through diet—such as fatty fish like salmon, sardines, and mackerel—is preferable to relying solely on supplements. Moreover, if you're considering adding fish oil supplements to your routine, it's advisable to consult with a healthcare provider to ensure they fit within your complete cardiovascular health strategy, which should also include a nutritious diet, regular exercise, and other heart-healthy lifestyle choices.
Based on user reviews, the time it takes to notice improvements from omega-3 supplements for cardiovascular disease can vary significantly. Many users start observing benefits within a month of regular consumption. For instance, one user reported a significant health improvement after over a month of use, which included enhanced immunity and improved skin condition (Read Review). Another user indicated that they noticed positive changes after three months of taking the supplement (Read Review).
Several other reviewers note ongoing benefits with sustained use beyond three months, with some mentioning substantial improvements in health after a year (Read Review). Overall, while initial results can often be felt within a month, more significant or lasting improvements may take three months or longer, depending on the individual's health status and consistency of use.
The scientific research strongly supports the use of omega-3 fatty acids, particularly those derived from fish oil like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for cardiovascular disease management. Studies have shown that these fatty acids reduce the risk of heart issues by improving lipid profiles, lowering triglyceride levels, and enhancing heart function [32]. For instance, one meta-analysis highlighted significant reductions in major cardiovascular events in high-risk patients who consumed EPA [19]. Furthermore, higher omega-3 levels were correlated with lower incidences of sudden cardiac death and overall cardiovascular mortality, reinforcing their protective role against cardiovascular conditions [37].
Research has also suggested that dietary changes combined with omega-3 supplementation can lead to greater improvements in heart health indicators, such as cholesterol levels and body weight [4]. A comprehensive study of over 336 hemodialysis patients indicated that those with lower levels of marine omega-3s faced a significantly higher risk of cardiovascular events, underscoring the importance of maintaining adequate omega-3 intake for heart health [33]. Overall, the evidence points towards omega-3 fatty acids being a beneficial addition to heart disease prevention and management strategies, making them an essential consideration for individuals looking to support their cardiovascular health.
Users have reported a variety of improvements in health symptoms associated with omega-3 supplementation, particularly concerning cardiovascular issues. Many reviewers noted that after consistent use for a month or longer, they experienced significant benefits—ranging from enhanced immunity to notable reductions in skin conditions. One user mentioned their headaches have decreased in frequency, while another saw improvements in vascular conditions on their face (Read Review). After three months, several individuals observed better cholesterol management and blood pressure normalization, contributing to a reduced risk of cardiovascular diseases (Read Review).
Long-term users reported sustained benefits, with some indicating that a year of regular intake had dramatically improved their skin health and overall vitality (Read Review). Additionally, many shared that omega-3 not only alleviated symptoms related to cardiovascular disease but also provided added bonuses like improved mood stability and decreased menstrual discomfort (Read Review). It's essential to remember that while these anecdotal experiences suggest positive outcomes for many, individual results can vary based on personal health conditions and adherence to dosing.
Users have reported that combining omega-3 supplements with other heart-healthy products can enhance their effectiveness in managing cardiovascular disease. One user mentioned taking two capsules every morning for improved cholesterol control and reduced inflammation, suggesting that consistency and timing can optimize outcomes (Read Review). Another highlighted the benefits of omega-3 in cleansing blood vessels of "bad" cholesterol, which indicates that it could work synergistically with other lifestyle changes like diet and exercise (Read Review).
In addition, several reviewers noted that ongoing usage alongside other heart-health supplements led to significant improvements in blood pressure and cholesterol levels, further contributing to reduced risks of heart-related issues (Read Review). However, users also caution the importance of selecting high-quality omega-3 formulations, as the effectiveness can depend on the specific dosages of EPA and DHA, especially for patients with existing cardiovascular conditions (Read Review). Thus, many have emphasized the necessity of consulting healthcare professionals when integrating multiple supplements into their routine to ensure optimal heart health benefits.
For those looking to harness the benefits of Omega-3 fish oil in treating cardiovascular disease, research suggests a high-dose approach may yield significant improvements. Specifically, studies indicate that a daily intake of anywhere between 2,000 to 4,000 mg of Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), taken consistently for at least one year can substantially enhance heart function. These improvements are measured by factors such as left ventricular ejection fraction and peak oxygen consumption [36]. However, taking lower doses or adhering to shorter treatment periods might not confer similar benefits for heart health [3].
Additionally, the presence of Omega-3s has shown to decrease the risk of major cardiovascular events and improve lipid profiles, making a compelling case for their inclusion in heart health management strategies. These fatty acids appear to play a protective role against heart rhythm disorders and cardiovascular diseases, especially when coupled with dietary changes [24]. While individual responses may vary due to genetic factors and other health conditions, maintaining a regime of high-dose Omega-3 supplementation under professional guidance could be a powerful approach in reducing cardiovascular risks [2].
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
We found a noteworthy connection indicating that higher levels of omega-3 fatty acids in the blood, especially DHA, may contribute to a lower risk of sudden cardiac death (SCD) and cardiovascular disease (CVD) mortality. Our results highlighted an inverse association, revealing that individuals with elevated DHA levels seemed to benefit from reduced incidence of serious cardiac events.
Notably, the summary hazard ratios we calculated showed significant decreases in risk for those with high DHA levels compared to those with lower levels. This suggests a promising cardio-protective effect of DHA, reinforcing its potential as a valuable nutrient for heart health. In conclusion, we observed that increasing DHA intake may be a critical factor in promoting better cardiovascular outcomes.
The results showcased significant reductions in cholesterol levels, body weight, and other critical indicators. Notably, those who incorporated fish oil saw even greater improvements in weight loss and blood sugar levels. This research suggests that pairing a healthy diet with fish oil can enhance cardiovascular outcomes.
Our findings revealed a significant connection: patients with lower levels of these essential fatty acids had a heightened risk of experiencing CV events and higher all-cause mortality. We found that those in the lower tertile of n-3 PUFA levels (below 5.06 weight percent) faced notably worse outcomes. Interestingly, those with moderate to high n-3 PUFA levels enjoyed a reduced risk of CV complications and even all-cause mortality, which indicates that increasing levels of EPA and DHA might be beneficial.
These insights suggest that maintaining healthy levels of marine n-3 PUFAs could be crucial for patients undergoing hemodialysis. We observed a potential threshold effect, indicating that risks of CV issues climb for those with n-3 PUFA levels below a certain point. This reinforces the importance of dietary omega-3 fatty acids for heart health, especially in vulnerable populations.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
Our findings suggest that including EPA in the diet can help improve heart function and reduce irregular heart rhythms linked to high-fat diets.
Our findings revealed that while levels of docosahexaenoic acid (DHA) were higher in EAT compared to SAT, EPA levels showed a significant correlation with serum EPA concentrations. This suggests that the EPA found in the body is likely to influence its presence in EAT. Additionally, we noted that both ALA and EPA levels in EAT were linked to lower levels of TNFα, a marker of inflammation.
However, we didn't find significant differences in EPA levels across the different tissue types among patients with or without atherosclerotic heart disease. Overall, while EPA and ALA are associated with potential anti-inflammatory effects for cardiovascular disease patients, further efforts to enhance serum EPA levels may be necessary to see increased availability in EAT.
In this study, 86 adults participated in a 4-week fish oil program, and their lipid profiles were assessed before and after the supplementation.
We found that genetic variations, specifically in the FADS1 and ELOVL2 genes, might affect how well the body utilizes omega-3 fatty acids.
This highlights the potential for personalized nutrition to enhance cardiovascular health.
References
- Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. doi:10.1002/biof.70014
- Medoro A, Graziano F, Cardinale G, Voccola S, Zotti T, et al. The influence of FADS1 and ELOVL2 genetic polymorphisms on polyunsaturated fatty acid composition in response to fish oil supplementation. Lipids Health Dis. 2025;24:102. doi:10.1186/s12944-025-02513-w
- Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. doi:10.1016/j.jphyss.2025.100014
- Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. doi:10.1186/s12944-025-02500-1
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Mao Q, Tian X, Wang X, Xu H, Zhang Y, et al. Global burden of cardiovascular diseases attributable to diet low in seafood omega-3 fatty acids from 1990~2021 and forecasting the future trends: A population-based study. PLoS One. 2025;20:e0316767. doi:10.1371/journal.pone.0316767
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. doi:10.1515/jcim-2024-0427
- Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. doi:10.1016/j.foodchem.2024.142498
- Dong S, Wang Y, Bian J, Chen H, Dong J, et al. The effect of omega-3 Polyunsaturated Fatty Acid (PUFA) prescription preparations on the prevention of clinical cardiovascular disease: a meta-analysis of RCTs. Nutr J. 2024;23:157. doi:10.1186/s12937-024-01051-y
- Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. doi:10.1016/j.mayocp.2024.08.007
- Brosolo G, Da Porto A, Marcante S, Capilupi F, Bertin N, et al. The role for ω-3 polyunsaturated and short chain fatty acids in hypertension: An updated view on the interaction with gut microbiota. Eur J Pharmacol. 2024;985:177107. doi:10.1016/j.ejphar.2024.177107
- Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. doi:10.1017/S0007114524002708
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Li ZH, Song WQ, Qiu CS, Li HM, Tang XL, et al. Fish oil supplementation, genetic susceptibility and risk of new-onset hypertension. Prev Med. 2024;189:108152. doi:10.1016/j.ypmed.2024.108152
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. doi:10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. doi:10.3390/jcdd12020060
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. doi:10.1016/j.prostaglandins.2025.106948
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. doi:10.3390/nu16213614
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. doi:10.1016/j.plefa.2024.102655
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. doi:10.1016/j.athplu.2024.09.002
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. doi:10.3390/ijms251810136
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. doi:10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. doi:10.3390/jcdd12020060
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. doi:10.1007/s11357-025-01544-6
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. doi:10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. doi:10.1039/d4fo04961f
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. doi:10.1016/j.prostaglandins.2025.106948
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. doi:10.3390/nu16233995
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. doi:10.1016/j.plefa.2024.102655
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. doi:10.1093/eurjpc/zwae315
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. doi:10.3390/ijms251810136
